Chronic Diseases Prevention Review

 Chronic Diseases Prevention Review (ISSN 2158-0820) is an international, peer-reviewed open access journal on chronic diseases. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. Chronic Diseases Prevention Review publishes highly significant studies in a broad range of chronic diseases and prevention research. The mission of Chronic Diseases Prevention Review is to promote the open exchange of information and knowledge among researchers, practitioners, policy makers, and others who strive to improve the health of the public through chronic disease prevention. The vision of Chronic Diseases Prevention Review is to be the premier forum where practitioners and policy makers inform research and researchers help practitioners and policy makers more effectively improve the health of the population. Articles focus on preventing and controlling chronic diseases and conditions, promoting health, and examining the biological, behavioral, physical, and social determinants of health and their impact on quality of life, morbidity, and mortality across the life span.
    Online ISSN: 2158-0820     About Open Access Journals

Vol. 11

NO.29 2024

Vol. 11

NO.30 2024
Article
The identification of potential inhibitors of SARS-CoV-2 spike protein by virtual screening FDA-approved compound library
by Zhujia Ren, Derong Zeng, Peiqing Wang, Rong Wang, Binqing Zhou, Yan Zhang .
Chronic Diseases Prevention Review 2024, 8(29), 1-4; - 25 Mar. 2024
Abstract
: Coronavirus disease 2019 (COVID-19) has an unprecedented global health crisis and economic disruptive impact, which is initiated by the spike protein of severe acute respiratory syndrome coronavirus (SARS-COV-2) binding to the angiotensin-converting enzyme 2 (ACE2) receptor of human cells. [...] Read more.
: Coronavirus disease 2019 (COVID-19) has an unprecedented global health crisis and economic disruptive impact, which is initiated by the spike protein of severe acute respiratory syndrome coronavirus (SARS-COV-2) binding to the angiotensin-converting enzyme 2 (ACE2) receptor of human cells. To identify potential inhibitors of SARS-CoV-2 spike protein, molecular docking-based virtual screening FDA-approved compound library was performed. Primaquine has more favorable docking scores than remdesivir, which are -8.910 and -5.725 kcal/mol, respectively. Primaquine formes hydrogen bonds with Glu35, Asp38, and Gly496 and cation-π interactions with Lys353, which contribute to the antiviral activity of primaquine. The study provides a valuable basis for the development of anti-novel coronavirus drugs. Open Access Download (free) PDF Full article
(This article belongs to the Section Chronic Diseases Prevention Review)
Back to TopTop